Docetaxel/anthracycline combinations for breast cancer treatment

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 4, 2007, Pages 485-495

  von Minckwitz, Gunter ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Anthracyclines; Breast cancer; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ERYTHROMYCIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMATOLOGIC AGENT; HORMONE RECEPTOR; KETOCONAZOLE; LAPATINIB; LERIDISTIM; METHOTREXATE; NAVELBINE; PACLITAXEL; PROTEIN BCL 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD CELL COUNT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HEART LEFT VENTRICLE EJECTION FRACTION; HORMONAL THERAPY; HUMAN; INFECTION; LEUKOPENIA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; PERITONITIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; SAFETY; TAXOIDS;

EID: 33947285105     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.4.485     Document Type: Review

References (37)

1. FIGGITT DP, WISEMAN LR: Docetaxel: an update of its use in advanced breast cancer. Drugs (2000) 59:621-651.
2. EISENHAUER EA, VERMORKEN JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs (1998) 5:5-30.
3. CERUTI M, TAGINI V, RECALENDA V et al.: Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions. Farmaco (1999) 54:733-739.
4. GANEM G, TUBIANA-HULIN M, FUMOLEAU P et al.: Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol. (2003) 14(11):1623-1628.
5. SMITH RE, ANDERSON SJ, LEMBERSKY BC, BROWN A, MAMOUNAS E: Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57. Clin. Breast Cancer (2004) 5:208-2015.
6. MILLER KD, MCCASKILL-STEVENS W, SISK J et al.: Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomised pilot trial of the Hoosier Oncology Group. J Clin. Oncol. (1999) 17(10):3033-3037.
7. MALHOTRA V, DORR VJ, LYSS AP et al.: Neoadjuvant and adjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast cancer. Clin. Breast Cancer (2004) 5(5):377-384.
8. SPARANO JA, O'NEILL A, SCHAEFER PL, FALKSON CI, WOOD WC: Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J. Clin. Oncol. (2000) 18:2369-2377.
9. MORALES S, LORENZO A, RAMOS M et al.: Docetazel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre Phase II study. Cancer Chemother. Pharmacol. (2004) 53(1):75-81.
10. NABHOLTZ JM, FALKSON C, CAMPOS D et al.; TAX 306 STUDY GROUP: Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomised, multicenter, Phase III trial. J Clin. Oncol. (2003) 21:959-962.
11. BONTENBAL M, CREEMERS GJ, BRAUN HJ et al.; DUTCH COMMUNITY SETTING TRIAL FOR THE CLINICAL TRIAL GROUP: Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J. Clin. Oncol. (2005) 23:7081-7088.
12. ALBA E, MARTIN M, RAMOS M et al.; SPANISH BREAST CANCER RESEARCH GROUP: Multicenter randomised trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) Phase III study. J. Clin. Oncol. (2004) 22(13):2587-2593.
13. BRAIN EG, BACHELOT T, SERIN D; RAPP-01 TRIAL INVESTIGATORS: Life-threatening sepsis associated with adjuvant doxorubicin plus docetaxel for intermediate-risk breast cancer. JAMA (2005) 293(19):2367-2371.
14. CROWN JP, FRANCIS P, DI LEO A et al.: Docetaxel (T) given concurrently with or sequentially to anthracydine-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 Trial at 5 years median follow-up (MFU). Proc. Am. Soc. Clin. Oncol. (2006) 24(Pt 1):18S.
15. EVANS TR, YELLOWLEES A, FOSTER E et al.: Phase III randomised trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J. Clin. Oncol. (2005) 23:2988-2995.
16. REITSAMER R, PEINTINGER F, PROKOP E, HITZL W: Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anti-Cancer Drugs (2005) 16:867-870.
17. VON MINCKWITZ G, COSTA SD, RAAB G et al.: Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomised, controlled, open Phase IIb study. J. Clin. Oncol. (2001) 19:3506-3515.
18. VON MINCKWITZ G, RAAB G, CAPUTO A et al.: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J. Clin. Oncol. (2005) 23:2676-2685.
19. RAAB G, KAUFMANN M, SCHUETTE M et al.: Preoperative doxorubicin/ cyclophosphamide followed by docetaxel (AC-Doc) versus dose-dense doxorubicin and docetaxel (Adoc) as preoperative treatment in operable breast cancer: first analysis of the event-free survival of the GeparDuo-Study. Breast Canc Res Treat (2005) 94(Suppl. 1):Abstr. 5047.
20. NABHOLTZ JM, MACKEY JR, SMYLIE M et al.: Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J. Clin. Oncol. (2001) 19:314-321.
21. MACKEY JR, PATERSON A, DIRIX LY et al.: Final results of the Phase III randomised trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2002) 21:Abstr. 137.
22. MARTIN M, PIENKOWSKI T, MACKEY J et al.; BREAST CANCER INTERNATIONAL RESEARCH GROUP 001 INVESTIGATORS: Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med. (2005) 352:2302-2313.
23. EIERMANN W, PIENKOWSKI T, CROWN J et al.; ON BEHALF OF THE BCIRG 005 INVESTIGATORS: Phase III randomised trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in Her-2/ neu negative early breast cancer patients with positive axillary lymph nodes: interim analysis of the BCIRG 005 study. Breast Canc. Res. Treat. (2005) 94(Suppl. I):Abstr. 1069.
24. VON MINCKWITZ G, BLOHMER JU, RAAB G et al.: In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann. Oncol. (2005) 16:56-63.
25. VON MINCKWITZ G, BLOHMER J, VOGEL P et al.: Comparison of neoadjuvant 6 versus 8 cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) in patients early responding to TACx2-the GEPARTRIO Study. Proc. Am. Soc. Clin. Oncol. (2006) 24(Pt 1):18S Abstr. 576.
26. VON MINCKWITZ G, BLOHMER JU, LOEHRA et al.: German Breast Group comparison of docetaxel/doxorubicin/cyclophosphamide (TAC) versus vinorelbine/capecitabine (NX) in patients non-responding to 2 cycles of neoadjuvant TAC chemotherapy first results of the Phase III GEPARTRIO-Study by the German Breast Group. Breast Canc Res Treat (2005) 94(Suppl.):Abstr. 38.
27. RISCHIN D, ACKLAND SP, SMITH J et al.: Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. Ann. Oncol. (2002) 13:1810-1818.
28. VENTURINI M, DEL MASTRO L, GARRONE O et al.: Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer. Ann. Oncol. (2002) 13:546-552.
29. WENZEL C, BARTSCH R, LOCKER GJ et al.: Preoperative chemotherapy with epidoxorubicin, docetaxel and capecitabine plus pegfilgrastim in patients with primary breast cancer. Anticancer Drugs (2005) 16:441-445.
30. SCHNEEWEISS A, HUOBER J, SINN HP et al.: Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre Phase I/II study. Eur. J. Cancer. (2004) 40:2432-2438.
31. ESTEBAN E, MODOLLEL A, GONZALEZ DE SANDE L et al.; GRUPO ONCOLOGICO DEL NORTE DE ESPANA: Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study. Breast Cancer Res. Treat. (2003) 80(3):257-265.
32. WENZEL C, HUSSIAN D, BARTSCH R et al.: Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J. Cancer Res. Clin. Oncol. (2004) 130:400-404.
33. WEDAM SB, LOW JA, YANG SX et al.: Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J. Clin. Oncol. (2006) 24:769-777.
34. VON MINCKWITZ G, BLOHMER JU, LÖHR A et al.: Primary prophylaxis with 3 weekly pegfilgrastim and ciprofloxacin effectively prevent (febrile) neutropenia and infection during neoadjuvant chemotherapy with docetaxel/ doxorubicin/cyclophosphamide (TAC) in breast cancer patients. Proc. Am. Soc. Clin. Oncol. (2005) 23:Abstr. 8008.
35. NABHOLTZ JM, CANTIN J, CHANG J et al.: J Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial. Clin Breast Cancer (2002) 3:268-275.
36. LOIBL S, VON MINCKWITZ G, ELLING D: Toxicity in elderly breast cancer patients treated by a taxane based chemotherapy as adjuvant or neoadjuvant therapy for primary breast cancer. Proc. Am. Soc. Clin. Oncol. (2006) 24(Pt 1):18S Abstr. 18509.
37. LYMAN G: Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy a review of the evidence. J. Natl Compr. Canc. Netw. (2005) 3(4):557-571.